Lupus Nephritis Care Pathway
Official title: Evaluation of a Lupus Nephritis Care Pathway Integrating Telemedicine and Clinical Pharmacist Practitioners
Run by Duke University · NCT07783152 · Data updated 2026-11-12
A small group of adults with lupus nephritis will try a team-based care path that uses telemedicine and pharmacist-led support to help manage their treatment and see if it improves adherence and outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Duke University Academic / other |
| Locations | 1 site (Durham, North Carolina) |
| Status | Recruiting |
| Started | October 14, 2026 |
| Main results expected | October 2028 |
| Study ends | December 2028 |
| Registry record updated | October 19, 2026 |
| Trial ID | NCT07783152 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with active lupus nephritis receiving care at Duke University Health System who can participate in telemedicine and consent to the study procedures.
✕Probably not a fit
Patients who do not engage with telemedicine or have unstable access to the health system may not experience benefits from the pathway.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study tests a Lupus Nephritis Care Pathway delivered via telemedicine and pharmacist practitioners, with physician oversight from rheumatology and nephrology. Approximately 25 adults with active lupus nephritis will participate, answering surveys and taking part in interviews while receiving protocol-driven adherence support and remote monitoring. The study aims to see if the pathway is feasible and acceptable, gather user feedback for improvements, and explore any early signals on medication adherence and clinical outcomes. Outcomes will include enrollment and retention metrics, patient-reported experiences, and preliminary clinical indicators. The setting is Duke University Health System with collaboration from the Rheumatology Research Foundation.
Why it matters
Potential benefit: If successful, the LN Care Pathway could improve medication adherence and support better clinical management for lupus nephritis patients.
How similar studies have gone: Prior similar approaches using pharmacist-led, telemedicine–based pathways have shown feasibility in complex rheumatic conditions, though this exact LN pathway is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Active patient at a Duke University Health System clinic * Current diagnosis of Systemic Lupus Erythematosus (SLE) based on the 1997 ACR,32 2012 Systemic Lupus International Collaborating Clinics (SLICC),33 or 2019 European League Against Rheumatism (EULAR)/ACR (American College of Rheumatology)34 classification criteria * Aged 18 years or older * Able to provide informed consent * Able to attend telemedicine visits * New onset or ongoing active LN based on rheumatologist or nephrologist evaluation Exclusion Criteria: * Patients with severe cognitive impairment * Do not wish to receive longitudinal care at our health system
Where it's running
-
Duke University
Durham, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Kai Sun, MD, MS — Duke University
- Study coordinator: Edna Scarlett
- Email: edna.scarlett@duke.edu
- Phone: 919-684-6150
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TranspoCART19 CAR-T therapy in adults with refractory lupus nephritis
This trial tests whether a patient’s own CD19 CAR-T cells can be safely given and potentially help adults with lupus nephritis that isn’t responding to standard treatments.
-
Initial glucocorticoid-dose harmonization in childhood lupus nephritis
This trial tests whether starting children with Lupus Nephritis on a lower or higher prednisone dose makes a difference in treatment outcomes.
-
See if empagliflozin helps kidney function in people with lupus nephritis
This study tests whether adding empagliflozin to standard care improves kidney function in adults with active lupus nephritis.
-
HB2198 for adults with moderate to severe lupus, including lupus nephritis and extra‑renal lupus
This trial will test whether two intravenous doses of HB2198 can safely reduce B cells and improve disease measures in adults with moderate to severe lupus, including lupus nephritis and extra‑renal lupus.
-
HSK39297 tablets for lupus nephritis
This trial will test whether once-daily oral HSK39297 (200 mg or 300 mg) is safe and well tolerated compared with placebo in adults with active lupus nephritis.
-
Comparing two biologic induction regimens and standard mycophenolate therapy for active proliferative lupus nephritis over six months
This trial will test whether biologic induction therapy with belimumab or telitacicept leads to better kidney responses over six months than standard mycophenolate-based treatment in people aged 14–65 with active proliferative lupus nephritis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.